We report a case of ectopic prostate tissue presenting as multiple lesions resembling a giant pelvic mass with seeding nodules. A 60-year-old man was admitted to the general surgery department of our hospital with an incidentally discovered pelvic mass on computed tomography performed at an outside hospital. The computed tomography scan showed a well-demarcated heterogeneous enhancing mass of 14 cm on the right side of the urinary bladder, and other similarly small nodules were observed in the pelvic cavity and perianal area. Physical examination showed a palpable mass in the suprapubic area; however, the patient did not complain of urinary system symptoms. Laboratory examination showed an elevated level of prostate-specific antigen (12.18 ng/mL). Suprapubic incision and mass resection were performed. The surgeon removed two of the masses and dissected the pelvic lymph nodes. Pathological examination confirmed that both masses were ectopic prostate tissues, and focal adenocarcinoma (<5%) was noted in the largest mass (Gleason score, 3 + 3 = 6). The Prostate-specific antigen level returned to normal postoperatively.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048055 | PMC |
http://dx.doi.org/10.1016/j.radcr.2022.03.008 | DOI Listing |
Dis Model Mech
January 2025
Laboratory Genes and Disease, Department of Laboratory Medicine, Medical University of Vienna (MUW), Vienna, Austria.
Genetically engineered mouse models (GEMMs) are instrumental for modelling local and systemic features of complex diseases such as cancer. Non-invasive, longitudinal cell detection and monitoring in tumors, metastases and/or the micro-environment is paramount to achieve a better spatiotemporal understanding of cancer progression and to evaluate therapies in preclinical studies. Bioluminescent and fluorescent reporters marking tumor cells or their microenvironment are valuable for non-invasive cell detection and monitoring in vivo.
View Article and Find Full Text PDFJ Cell Physiol
January 2025
Department of Anatomy, College of Medicine, Chang Gung University, Kwei-Shan, Taiwan.
Glucose can activate the carbohydrate response element binding protein (ChREBP) transcription factor to control gene expressions in the metabolic pathways. The way of ChREBP involvement in human prostate cancer development remains undetermined. This study examined the interactions between prostate fibroblasts and cancer cells under the influences of ChREBP.
View Article and Find Full Text PDFRev Endocr Metab Disord
November 2024
Departamento de Biología de Sistemas. Unidad de Bioquímica y Biología Molecular (Research group "Cánceres de origen epitelial"), Universidad de Alcalá, Campus Científico-Tecnológico, 28871, Alcalá de Henares, Madrid, Spain.
Adv Healthc Mater
January 2025
School of Biomedical Sciences, Faculty of Health, and Translational Research Institute (TRI), Queensland University of Technology (QUT), Brisbane, QLD, 4102, Australia.
Bone tissue engineering (BTE) has long sought to elucidate the key factors controlling human/humanized bone formation for regenerative medicine and disease modeling applications, yet with no definitive answers due to the high number and co-dependency of parameters. This study aims to clarify the relative impacts of in vitro biomimetic 'preculture composition' and 'preculture duration' before in vivo implantation as key criteria for the optimization of BTE design. These parameters are directly related to in vitro osteogenic differentiation (OD) and mineralization and are being investigated across different osteoprogenitor-loaded biomaterials, specifically fibrous calcium phosphate-polycaprolactone (CaP-mPCL) scaffolds and gelatin methacryloyl (GelMA) hydrogels.
View Article and Find Full Text PDFFront Nucl Med
November 2023
Department of Radiation Oncology, German Oncology Centre, University Hospital of the European University, Limassol, Cyprus.
Background: 18F-prostate specific membrane antigen (PSMA) PET is fast becoming the gold-standard in prostate cancer, both in staging of intermediate-/high-risk patients and in re-staging patients with biochemical failure. Several pitfalls of 18F-PSMA PET have been reported, and we report, to our best of knowledge, for the first time, a case which could have been falsely diagnosed as peritoneal spread.
Case Presentation: A 67-year-old patient with high-risk prostate cancer underwent staging with 18F-PSMA-1007 PET/CT (PSMA-PET/CT).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!